The University of Southampton
University of Southampton Institutional Repository

The evolving pharmacological landscape for pediatric and adult ADHD

The evolving pharmacological landscape for pediatric and adult ADHD
The evolving pharmacological landscape for pediatric and adult ADHD

While attention-deficit/hyperactivity disorder (ADHD) medications, particularly stimulants, are among the most effective treatments in psychiatry, there remains a need for novel alternatives, as not all individuals with ADHD respond to or tolerate currently available medications. We aimed to provide an up-to-date overview of randomised controlled trials (RCTs) of agents either not approved for ADHD or approved for ADHD but tested for off-label indications. We updated, using the same methodology, two previous reviews (Cortese et al, 2023 exploring agents in the pipeline for children with ADHD, and Veronesi et al, 2024, focusing on RCTs of novel compounds in adults with ADHD). For the update, we searched ClinicalTrials.gov and the European Union-based EU Clinical Trials registers up to December 14, 2025. Including the RCTs retrieved by the two previous reviews and those from the updated search, we identified a total of 53 eligible RCTs. Of these, 11 reported results in children and adolescents, and 11 in adults. Considering agents with at least two positive trials for ADHD core symptoms without negative trials, only dasotraline, in children, and centanafadine, in adults, emerged as promising (however, the dasotraline development programme was halted in 2020). This review also includes a discussion of opportunities for advancing the development of novel, effective agents and maximising the benefits of currently available options.

1172-7047
901-920
Fusetto Veronesi, Guilherme
4af0a76e-8657-4b99-b174-027605ef63dc
Tarantino, Fabio
a14d04b9-b967-4790-aaad-df2fa1a1c3b3
Pirolo, Daniele
c6f03ff1-f4e8-4869-b449-026d92831c8c
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Fusetto Veronesi, Guilherme
4af0a76e-8657-4b99-b174-027605ef63dc
Tarantino, Fabio
a14d04b9-b967-4790-aaad-df2fa1a1c3b3
Pirolo, Daniele
c6f03ff1-f4e8-4869-b449-026d92831c8c
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb

Fusetto Veronesi, Guilherme, Tarantino, Fabio, Pirolo, Daniele and Cortese, Samuele (2026) The evolving pharmacological landscape for pediatric and adult ADHD. CNS drugs, 40 (7), 901-920. (doi:10.1007/s40263-026-01299-4).

Record type: Article

Abstract

While attention-deficit/hyperactivity disorder (ADHD) medications, particularly stimulants, are among the most effective treatments in psychiatry, there remains a need for novel alternatives, as not all individuals with ADHD respond to or tolerate currently available medications. We aimed to provide an up-to-date overview of randomised controlled trials (RCTs) of agents either not approved for ADHD or approved for ADHD but tested for off-label indications. We updated, using the same methodology, two previous reviews (Cortese et al, 2023 exploring agents in the pipeline for children with ADHD, and Veronesi et al, 2024, focusing on RCTs of novel compounds in adults with ADHD). For the update, we searched ClinicalTrials.gov and the European Union-based EU Clinical Trials registers up to December 14, 2025. Including the RCTs retrieved by the two previous reviews and those from the updated search, we identified a total of 53 eligible RCTs. Of these, 11 reported results in children and adolescents, and 11 in adults. Considering agents with at least two positive trials for ADHD core symptoms without negative trials, only dasotraline, in children, and centanafadine, in adults, emerged as promising (however, the dasotraline development programme was halted in 2020). This review also includes a discussion of opportunities for advancing the development of novel, effective agents and maximising the benefits of currently available options.

Text
V2_clean - Accepted Manuscript
Restricted to Repository staff only until 21 May 2027.
Available under License Other.
Request a copy
Text
Table 1_resubmission_v2 - Accepted Manuscript
Restricted to Repository staff only until 21 May 2027.
Available under License Other.
Request a copy
Text
Supplementary Information_v2 - Accepted Manuscript
Restricted to Repository staff only until 21 May 2027.
Available under License Other.
Request a copy

More information

Accepted/In Press date: 20 April 2026
e-pub ahead of print date: 21 May 2026
Published date: 21 May 2026

Identifiers

Local EPrints ID: 512044
URI: https://eprints.soton.ac.uk/id/eprint/512044
ISSN: 1172-7047
PURE UUID: 8e08461f-94b5-4d51-bddb-2917242dacd3
ORCID for Guilherme Fusetto Veronesi: ORCID iD orcid.org/0009-0005-0117-6571
ORCID for Samuele Cortese: ORCID iD orcid.org/0000-0001-5877-8075

Catalogue record

Date deposited: 15 Jun 2026 16:36
Last modified: 13 Sep 2026 15:48

Export record

Altmetrics

Contributors

Author: Guilherme Fusetto Veronesi ORCID iD
Author: Fabio Tarantino
Author: Daniele Pirolo
Author: Samuele Cortese ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×